Sector News

Boston Scientific Elects Charles J. Dockendorff And Stephen P. MacMillan To Board Of Directors

March 4, 2015
Life sciences
/PRNewswire/ – Boston Scientific Corporation announces the election of Charles J. Dockendorff and Stephen P. MacMillan to its board of directors, effective April 1, 2015. Two current members of the board, Uwe E. Reinhardt and Bruce L. Byrnes, will not stand for re-election at the company’s annual meeting of stockholders in May 2015.
 
Charles J. Dockendorff was formerly the executive vice president and chief financial officer of Covidien plc. Mr. Dockendorff currently serves on the board of directors of Haemonetics Corporation and Keysight Technologies. He received his B.A. in Business Administration and Accounting from the University of Massachusetts at Amherst and received his Master of Science in Finance from Bentley College.
 
Stephen P. MacMillan is currently the president and chief executive officer of Hologic, a leading global healthcare and diagnostics company. Previously, Mr. MacMillan served as president and chief executive officer of Stryker Corporation. He currently serves on the board of directors of Alere Inc. Mr. MacMillan received a Bachelor of Arts degree in Economics from Davidson College and is a graduate of Harvard Business School’s Advanced Management Program.
 
“We are thankful for the guidance and years of dedicated service that Dr. Reinhardt and Mr. Byrnes contributed to Boston Scientific, and we are pleased to welcome Mr. Dockendorff and Mr. MacMillan to our board,” said Pete Nicholas, chairman of the board, Boston Scientific Corporation. “Their extensive experience and management insights will be valuable additions as we continue to deliver meaningful innovation to address the unmet needs of patients around the world.”
 
Dr. Reinhardt, who has served as a director of Boston Scientific since May 2002, is the James Madison Professor of Political Economy and Professor of Economics and Public Affairs at Princeton University. Dr. Reinhardt is a senior associate of the University of Cambridge, England and serves as a Trustee of H&Q Healthcare Investors and H&Q Life Sciences Investors. He is also the Commissioner of the Kaiser Family Foundation Commission on Medicaid and the Uninsured.
 
Mr. Byrnes, who has served as a director of Boston Scientific since August 2009, is a retired vice chairman of the board for The Procter and Gamble Company who worked with several global divisions, including healthcare during his 38-year career. Mr. Byrnes is a director of Brown Forman Corporation and Diebold, Incorporated. He previously served as a director of Cincinnati Bell, Inc. and a trustee of the Cincinnati Art Museum.
 
Source: Boston Scientific 

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.